Open Orphan is rapidly developing into a leading European rare disease and orphan drug focused pharma services company. Venn Life Sciences – part of the Open Orphan plc family: Read More

Your Partners for Drug and Medical Device Development

European Focus – International Coverage

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of pre-clinical and CMC drug development expertise, clinical trial design and management. This enables us to create, plan and execute drug and medical device development programs effectively and seamlessly for our clients.

CLIENT TESTIMONIAL
“We have been delighted to work with Venn Life Sciences on this complex clinical trial. Their commitment to quality coupled with an in-depth knowledge of running Investigator Initiated Studies has facilitated the effective and efficient management of the various activities and requirements associated with the study. We fully expect that together we will bring the trial to completion on time and on budget.”
Professor Keith G. Oldroyd, Director of Research and Development West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital
NEWS & EVENTS
11Feb

Is your organisation ready for the ICH E9 (R1) regulatory updates

0 Comments
How will this impact your development programs from a regulatory perspective. Get updates on the FDA guidance on Demonstrating Substantial... Read More →
07Jan

Venn Life Sciences part of Open Orphan plc in German pharma deal

0 Comments
Ellie Donnelly : January 7th 2020 – You can view this article at : independent.ie Long-term: CEO Cathal Friel says... Read More →
19Nov

New contract with Carna Bioscience

0 Comments
Contract signed with Carna Bioscience Venn Life Sciences, part of Open Orphan plc announce the signing of a contract with... Read More →
CONTACT US

march

23maralldayalldayBiotech Partnering Conference | Bio-Europe 2020

Above are the current and upcoming events for the year that you will find Venn Life Sciences attending. Click to view the Events Calender.
Back to Top
X